Dehydroepiandrosterone

ApprovedSmall molecule

Dehydroepiandrosterone is one of 210 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.

Indications

Total Trials

Active Trials

209

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Primary Adrenal InsufficiencyActive, not recruiting

Mood DisorderActive, not recruiting

Adrenal InsufficiencyActive, not recruiting

Skin AgingActive, not recruiting

Anorexia NervosaActive, not recruiting

Ovarian ReserveActive, not recruiting

Breast CancerActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

Systemic Lupus ErythematosusPhase 2/Phase 3

Active, not recruiting

Primary Adrenal InsufficiencyPhase 3

Active, not recruiting

Mood DisorderPhase 2

Active, not recruiting

Adrenal InsufficiencyPhase 3

Active, not recruiting

Skin AgingPhase 3

Active, not recruiting

Anorexia NervosaPhase 2/Phase 3

Active, not recruiting

Ovarian ReservePhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Type 1 Diabetes MellitusPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Dehydroepiandrosterone

IInflabloc Pharmaceuticals

Approved

2 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

MS Contin

Merck & Co.

Preclinical

2 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Breast Cancer

NCT05562518

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus5 trials

Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus

Completed·NNational Center for Research Resources (NCRR)·Phase 2/3·NCT00004795·190 enrolled

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

Completed·UUniversity of Michigan·Phase 2/3·NCT00189124·13 enrolled

Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004665·20 enrolled

Show 2 more trials

Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome

Completed·UUMC Utrecht·Phase 2·NCT00391924·120 enrolled

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus

Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004662·300 enrolled

Ovarian3 trials

Effect of DHEA on Patients With Poor Ovarian Responds

Unknown status·TThe Affiliated Hospital of Inner Mongolia Medical University·N/A·NCT02432248·350 enrolled

Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging

Completed·UUniversity of Nottingham·Phase 3·NCT01572025·60 enrolled

The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders

Unknown status·—·Phase 2/3·NCT05900661·300 enrolled

Breast Cancer2 trials

GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.

Recruiting·UUniversity Hospital, Ghent·Phase 4·NCT05562518·160 enrolled

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

Terminated·UUniversity of Arkansas·Phase 2·NCT04493333·8 enrolled

Sjogren's Syndrome1 trial

DHEA Treatment for Sjogren's Syndrome

Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00001598·28 enrolled

Postmenopausal Women1 trial

Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms

Completed·MMonash University·Phase 3·NCT00289926·240 enrolled

13 more indications

Mood Disorder1 trial

Treatment of Mid-Life-Related Mood Disorders

Completed·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00001487·60 enrolled

Fatigue1 trial

Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue

Unknown status·UUniversity of Helsinki·Phase 4·NCT00543166·107 enrolled

Skin Aging1 trial

Effect of DHEA on Skin Aging in Postmenopausal Women

Completed·—·Phase 3·NCT00248989·150 enrolled

Type 1 Diabetes Mellitus1 trial

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

Completed·UUniversity of Maryland, Baltimore·Phase 1·NCT00607646·50 enrolled

Vaginal Delivery1 trial

Pharmacokinetics of a Novel Vaginal Delivery System for Testosterone and Dehydroepiandrosterone (DHEA)

Completed·LLaboratorios Andromaco S.A.·Phase 1·NCT03967964·46 enrolled

Ovarian Reserve1 trial

Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve

Completed·TTaipei Veterans General Hospital, Taiwan·Phase 3·NCT02150330·40 enrolled

Anorexia Nervosa1 trial

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

Completed·—·Phase 2/3·NCT00310791·80 enrolled

Renal Failure1 trial

Six Months DHEA Treatment in Female Adrenal Failure

Completed·UUniversity of Aarhus·N/A·NCT00471900·10 enrolled

Efficacy and Safety1 trial

An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease

Completed·IInflabloc Pharmaceuticals·Phase 2·NCT00106314·75 enrolled

Treatment1 trial

Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT00916396·50 enrolled

IVF Outcome1 trial

Does DHEA IVF Outcomes in Poor Responders?

Suspended·—·Phase 2/3·NCT04066478·400 enrolled

Adrenal insufficiency1 trial

Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency

Completed·UUniversity Hospital Tuebingen·Phase 3·NCT00575341·23 enrolled

Primary Adrenal Insufficiency1 trial

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency

Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004313·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for Dehydroepiandrosterone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dehydroepiandrosterone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dehydroepiandrosterone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inflabloc Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IInflabloc Pharmaceuticals

Dehydroepiandrosterone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Systemic Lupus Erythematosus5 trials

Ovarian3 trials

Breast Cancer2 trials

Sjogren's Syndrome1 trial

Postmenopausal Women1 trial

Mood Disorder1 trial

Fatigue1 trial

Skin Aging1 trial

Type 1 Diabetes Mellitus1 trial

Vaginal Delivery1 trial

Ovarian Reserve1 trial

Anorexia Nervosa1 trial

Renal Failure1 trial

Efficacy and Safety1 trial

Treatment1 trial

IVF Outcome1 trial

Adrenal insufficiency1 trial

Primary Adrenal Insufficiency1 trial

References

Drug Info

Quick Facts

Related News